CLL
AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment
September 4, 2023Medical Communications AstraZeneca, CLL, China, Oncology, SLL
AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …
Janssen CLL treatment combination sees success in trials
June 14, 2021Sales and Marketing CLL, Janssen
Janssen has announced positive data from its Phase III GLOW study, with the combination of imbruvica (ibrutinib) plus venetoclax (I+V) …
NICE approves Imbruvica for second-line leukaemia treatment
January 26, 2017Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica
NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …
Genmab’s CLL drug gets negative opinion from EMA committee
June 24, 2016Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer
Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …
AbbVie, Janssen’s Imbruvica gets European approval to teat CLL
May 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, CLL, drug trial, regulation
AbbVie (NYSE: ABBV) on Tuesday said Imbruvica (ibrutinib) has secured European regulatory backing to treat chronic lymphocytic leukemia or CLL. …
Novartis seeks expanded Arzerra use in US
March 11, 2016Research and Development Arzerra, CLL, FDA, Genmab, Novartis
Novartis has submitted a supplemental Biologics License Application (sBLA) to the US FDA for the use of Arzerra (ofatumumab) in …
Janssen slams NICE decision on Imbruvica
March 2, 2016Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica
Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …
Arzerra approved by US FDA for leukaemia
January 20, 2016Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application
The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …
Abbvie and Roche report success in Phase II leukaemia trial
August 13, 2015Research and Development AbbVie, Breakthrough Therapy Designation, CLL, EMA, FDA, Roche, chronic lymphocytic leukaemia, leukaemia, venetoclax
AbbVie plans to submit regulatory applications for its leukaemia drug venetoclax to the FDA and the EMA before the end …
ASCO 2015 roundup: immuno-oncology hits its stride
June 8, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, BMS, CLL, pdl1
One year can make all the difference. The 2014 American Society of Clinical Oncology (ASCO) meeting took place just weeks …
NICE signs-off Roche’s Gazyvaro for leukaemia
June 2, 2015Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia
NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …
NICE backs GSK’s leukaemia drug Arzerra following price cut
November 4, 2014Sales and Marketing Arzerra, CLL, GSK, NHS, NICE, leukaemia
NICE has recommended that GlaxoSmithKline’s Arzerra be prescribed under the NHS for patients with chronic lymphocytic leukaemia (CLL), after a …
Roche and Pharmacyclics agree leukaemia pact
October 17, 2014Research and Development, Sales and Marketing BMS, CLL, Cancer, Gazyva, Pharmacyclics, Roche, imbruvica, leukaemia
Pharmacyclics’s cancer drug Imbruvica will be tested in combination with Roche’s Gazyva in a new partnership announced by the firms. …
Roche falls foul of NICE rules, again
October 3, 2014Medical Communications, Sales and Marketing CLL, Gazyvaro, NICE, Roche, blood cancer, oncology
Uncertainties in the data and high cost have seen NICE make an initial rejection of Roche’s new blood cancer drug …
Gilead’s blood cancer pill approved in Europe
September 22, 2014Sales and Marketing CLL, Gilead, blood cancer, fl, idelalisib, oncology, zydelig
Gilead has gained European Commission approval for its new blood cancer pill Zydelig (idelalisib) as it looks to expand further …
Latest content
Five Facts about cardiovascular disease
